Navigation Links
Catalyst Pharmaceutical Partners to Present at the MoneyShow Conference
Date:5/7/2010

CORAL GABLES, Fla., May 7 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that Jack Weinstein, Catalyst's Chief Financial Officer, will be making a presentation at the MoneyShow Conference to be held May 10th through May 13th at Caesars Palace in Las Vegas.  Catalyst will present a Corporate Overview, including its development plans for CPP-109 and CPP-115. Further, the Company reported that its presentation materials from the conference will be posted on May 11th on the Company's website under "Events and Presentations."

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction, epilepsy and neuropathic pain. Catalyst has two products in development, and is currently evaluating the lead product candidate, CPP-109 (vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction, which indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address an unmet medical need. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. Catalyst is also in the early stages of developing CPP-115, another GABA aminotransferase inhibitor that could be more potent than vigabatrin but may have reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including epilepsy, neuropathic pain and drug addiction. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to GABA aminotransferase. For more information about the Company, go to www.catalystpharma.com.


'/>"/>
SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Catalyst Pharmaceutical Partners Regains Compliance with NASDAQ Minimum Bid Price Rule
2. Catalyst Pharmaceutical Partners to Present at the BioNetwork East 2010 Conference
3. Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
4. Catalyst Pharmaceutical Partners Selected to Present at Epilepsy Conference Highlighting New and Promising Therapies
5. IDEXX Laboratories Announces Catalyst Dx(R) Placement Total for 2009 and Installed Base of SmartService(TM) Customers
6. Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
7. Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executives Employment Agreement
8. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
9. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
10. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
11. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... CHICAGO , May 30, 2017 Hill-Rom Holdings, ... th Annual Global Healthcare Conference on Tuesday, June 13, ... John Greisch , Hill-Rom,s president and chief executive officer, ... The live audio webcast can be accessed at ... after conclusion of the live event through September 13, 2017. ...
(Date:5/29/2017)... TEL AVIV, Israel, May 29, 2017  Cellect Biotechnology ... of innovative technology which enables the functional selection of ... financial results for the first quarter ended March 31 ... pleased with our accomplishments in the first quarter of ... the first quarter, we announced the treatment of the ...
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Canadian Zeolite Corp. ... a two year study conducted by the University of Saskatchewan in partnership with ... remediating potash brine-impacted groundwater. As a part of the study, batch adsorption experiments ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with the ... for families with children receiving treatment in nearby hospitals. , Ronald McDonald House ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Harbour ... manage token assets on the Ethereum blockchain, has released their technical specifications . ... now, there has been little systematic approach for determining which offerings will garner the ...
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, EarQ ... was held in Syracuse, New York, where EarQ is headquartered. , Together, the ... to connect with today’s savvy consumer, and the latest in hearing technology. At ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... experts to contribute to an upcoming case studies guidebook. This guidebook offers an ... , This book will include articles, case studies and how-to’s that fall into ...
Breaking Medicine News(10 mins):